Evidence-Based Sex Hormone Optimization for Brain, Heart, Bone, and Metabolic Health With a Focus on Whole-Body Recovery

Abstract

As a healthcare provider with extensive experience in functional and integrative medicine, I have dedicated my career to improving patient outcomes by looking beyond conventional symptom management. This post aims to demystify hormone optimization, with a particular focus on estrogen, by presenting the latest evidence-based research from leading scientists. We will dismantle long-held myths, such as the link between estrogen and cancer, and explore the profound, system-wide benefits of hormone optimization. This educational piece will delve into the physiological roles of estrogen, progesterone, and testosterone in crucial areas like bone health, brain function, cardiovascular protection, and even cancer prevention. By shifting from an allopathic, symptom-focused model to a root-cause, preventative approach, we can empower our patients to achieve true homeostasis and long-term wellness. We will examine the flawed data from the Women’s Health Initiative (WHI) and discuss significant updates from major medical bodies, such as the North American Menopause Society (NAMS). This comprehensive overview will provide the scientific foundation needed to confidently integrate bioidentical hormone therapy into clinical practice, ultimately teaching our patients how not to be sick.

Hello, I’m Dr. Alex Jimenez. With my background as a Doctor of Chiropractic, Advanced Practice Registered Nurse, and board-certified Family Nurse Practitioner, along with certifications in functional medicine, my clinical practice is deeply rooted in a modern, evidence-based approach. For over a decade, I have focused on therapies that are truly life-changing for my patients, ranging from teenagers to older adults. Having performed tens of thousands of procedures, I’ve seen firsthand the incredible impact of optimizing health from the inside out.

One of the most important principles in this field is the need for continuous learning. I constantly refresh my knowledge because science is always evolving. Even after years of practice, I find that hearing information from different perspectives and experiences illuminates new facets of patient care. When you start applying these principles and see the results in your patients, the concepts truly click.

Shifting the Healthcare Paradigm: From Symptom Management to Root-Cause Resolution

The greatest gift we can give our patients is teaching them how to avoid getting sick. Our current healthcare system is largely reactive; we wait for illness and then manage it. The allopathic model is straightforward: a patient presents with a symptom, and we prescribe a medication to address that symptom. This weekend, I want to encourage a paradigm shift. Instead of just patching up complaints, let’s look under the hood. Let’s peel back the layers and ask, “Where is this disease coming from?”

Disease is not a normal state of being. Our goal should be to guide our patients back to homeostasis, a state of natural balance. This requires moving beyond the mindset that medicine is the only answer and embracing a practice that prevents disease before it starts.

The Truth About Estrogen: Beyond Hot Flashes and Misconceptions

I want to begin with estrogen, a hormone that often comes with a great deal of fear and misinformation. For most women, the primary concern when discussing hormones is the perceived link between estrogen and breast cancer. I am here to lay these myths to rest with solid scientific data.

The first crucial concept to understand is that hormone receptors are present on every single cell in the human body. Every organ system, from your brain to your bones, has receptors for sex hormones (estrogen, progesterone, and testosterone) and thyroid hormones. This fundamental biological fact refutes the simplistic notion that estrogen is only for hot flashes or that testosterone is only for erectile function.

The allopathic model might suggest giving a woman a pill to “simmer down” her hot flashes. The functional medicine model, which I champion, recognizes that this woman needs estrogen to prevent osteoporosis, cardiovascular disease, dementia, and even certain cancers. In fact, compelling research from the last several years indicates that estrogen is actually breast-protective and preventative against breast cancer—the exact opposite of what we have been taught for decades.

Hormones work by binding to their specific receptors. Estrogen binds to estrogen receptor alpha or beta, progesterone to the progesterone receptor, and androgens to the androgen receptor. This is where a critical distinction must be made. Synthetic hormones, such as progestins, are not identical to our body’s natural hormones. When a molecule that the receptor was not designed for, such as a progestin, binds to the receptor, it doesn’t elicit a beneficial action. Instead, it can block the receptor, preventing the natural hormone from doing its job. Understanding this receptor-level activity is a cornerstone of hormone optimization.

Estrogen’s extensive roles include:

• Female Sexual Health: Enhancing libido and vaginal health.
• Metabolism: Acting as a metabolic steroid.
• Inflammation: Serving as a powerful anti-inflammatory and immunomodulating agent.
• Bone Density: Protecting against osteoporosis and reducing the risk of colon cancer.
• Pain Management: Directly affecting pain processing pathways.
• Brain Health: Vital for mood, memory, cognition, and preventing neurodegeneration.

Estrogen is synthesized from cholesterol primarily in the ovaries and, to a lesser extent, the adrenal glands. It is lipophilic, meaning it can easily cross the blood-brain barrier to interact with receptors in the brain. The most potent and beneficial form of estrogen is 17-beta estradiol. This is the form we should use to optimize levels in postmenopausal women and is also the form that men produce via the aromatization of testosterone. Yes, estrogen is a powerful and necessary hormone for men as well.

The Women’s Health Initiative (WHI): Unraveling Two Decades of Misinformation

The fear surrounding estrogen largely stems from the misinterpretation and misrepresentation of the Women’s Health Initiative (WHI) study data. The media and some epidemiologists dangerously promoted the idea that all hormone therapy products have a single, negative class effect. This was a catastrophic error.

The study used Premarin (a synthetic estrogen derived from horse urine) and medroxyprogesterone acetate (Provera) (a synthetic progestin). The negative outcomes—increased risk of breast cancer, heart attacks, and strokes—were almost entirely confined to the arm of the trial that used the synthetic progestin. In stark contrast, the estrogen-only arm of the WHI actually showed a protective effect against breast cancer, heart attack, and stroke.

Essentially, we took the results from a hazardous drug (the synthetic progestin) and wrongly applied them to all hormones, including bioidentical ones. It has taken over 20 years to begin unraveling this damage. In a monumental move, the FDA, prompted by the work of Dr. M.J. Minkin and others, finally began lifting the black box warnings on estrogen, acknowledging that the evidence does not support the claim that it increases these risks (Minkin et al., 2017).

In 2017, the North American Menopause Society (NAMS) updated its position, recognizing that the WHI findings could not be generalized to younger, healthier women starting hormone therapy in early menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had underlying diseases. NAMS concluded there is no evidence to support the routine discontinuation of hormone therapy in women over 65 and advocated for an individualized approach (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017). This provides us, as clinicians, the professional liberty to do what we are trained to do: assess our patients, weigh the risks and benefits, and create a personalized plan that aligns with their health goals.

The System-Wide Benefits of Hormone Optimization

Let’s explore the specific, evidence-based benefits of maintaining optimal hormone levels across various body systems.

Enhancing Bone Health

We are all aware that estrogen is crucial for bone health, helping protect against osteoporosis. Less well known is that estrogen, progesterone, and testosterone all play vital roles in bone metabolism. Hormone receptors for all three are found on osteoblasts (bone-building cells), osteoclasts (cells that break down bone), and osteocytes. Wherever there is a receptor, there is a biological need.

• A 1996 study demonstrated that discontinuing hormone replacement therapy (HRT) leads to a significant decline in bone density (The Writing Group for the PEPI Trial, 1996).
• A 1999 study found that adding testosterone to estrogen therapy in postmenopausal women resulted in a more significant increase in bone mineral density than estrogen alone, highlighting the synergistic effect of androgens (Davis et al., 1999).
• Another study showed that combining estrogen with progesterone had an additive effect, resulting in better bone density outcomes than estradiol alone (Sørensen et al., 1990).

This research makes it clear that a comprehensive approach that considers all three sex hormones is necessary for optimal bone protection.

Protecting the Brain and Preventing Neurodegeneration

This is an area where the evidence is particularly exciting. As a practitioner who has managed the devastating consequences of strokes and dementia, knowing that we have tools to prevent and slow the progression of these diseases is truly empowering.

Both estrogen and testosterone are profoundly neuroprotective. Women have a higher incidence of Alzheimer’s disease than men, and this risk skyrockets with the loss of estrogen during menopause.

• Early research showed that estrogen and testosterone decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, the hallmark of Alzheimer’s disease.
• A key paper clarified a point of confusion: it is progestins (synthetic) that can block estrogen’s neuroprotective benefits and are associated with negative cognitive outcomes, not natural progesterone, which is synergistic with estrogen in the brain (Carroll & Pike, 2008). This is why we must not use progestins in our hormone regimens.
• A 2022 review paper described estrogen as a “key player in the neurobiology of aging” due to the extensive interconnectivity of the neural and endocrine systems (St-Pierre et al., 2022). It emphasized that the complex interactions between estrogen, progesterone, and androgens are all critical for brain health. This supports my life’s work of making testosterone therapy a standard of care for women.

A stunning PET scan study visualized the rapid brain changes that occur after menopause. Researchers scanned a woman’s brain during perimenopause and again three years post-menopause. The images clearly showed a dramatic increase in beta-amyloid deposits—those white, “dead” areas—in the brains of animals deprived of estrogen (Mosconi et al., 2017). The key takeaway is that beta-amyloid deposition begins a decade before cognitive symptoms appear. Prevention is paramount; we cannot wait for the damage to become irreversible.

Estrogen receptors are abundant in brain regions critical for learning, memory, and the regulation of circadian rhythms, such as the hypothalamus. They modulate neural differentiation, inflammation, and synaptic plasticity. Recent studies confirm that bioidentical estradiol and progesterone are profoundly neuroprotective and immunomodulatory, protecting against cell death and even stimulating the birth of new neurons (A. G. G. Ahmed & El-Maraghy, 2023).

Defending Against Stroke and Ischemic Injury

The neuroprotective effects of estrogen extend to cerebrovascular events like stroke. Estrogen not only protects the brain from ischemic injury but can also help prevent strokes from occurring in the first place.

• When an ischemic stroke occurs, estrogen helps mediate the subsequent immune cascade in a positive way, limiting the advancement of injury.
• One study showed that administering estradiol to patients experiencing a stroke significantly reduced proteins that promote cell death and increased proteins involved in cell survival (Raval et al., 2015). Imagine if estradiol became a standard part of acute stroke protocols. We are far from that reality, as many neurologists still incorrectly believe estrogen causes strokes.
• Following a brain injury, the body rapidly increases local estradiol production at the site of injury via the enzyme aromatase. This is the body’s innate wisdom at work; it’s making this protective molecule because there is an urgent need for it.

Supporting Cardiovascular Health

The same protective mechanisms at play in the brain also apply to the heart. Cardiovascular disease is an inflammatory condition, and estrogen is a powerful anti-inflammatory agent.

• The ELITE trial showed that healthy postmenopausal women who started estrogen therapy early experienced a 50% reduction in the rate of atherosclerosis progression compared to a placebo group (Hodis et al., 2016). Estrogen slows down plaque buildup.
• Optimal estrogen levels are also associated with improvements in lipid profiles and reductions in visceral fat. As I transitioned through menopause myself, I finally understood what my female patients had been telling me for years about the sudden accumulation of belly fat. The loss of estrogen disrupts fat distribution. Bioidentical estradiol is a visceral fat shredder, contrary to the myth that it causes weight gain.
• Abruptly stopping estrogen therapy, especially oral synthetic forms, has been shown in multiple studies to cause a statistically significant increase in the risk of stroke and heart attack death in the first year post-treatment. If a patient must stop therapy, it should be a gradual, tapered process.

The Crucial Role of Estrogen in Men

For years, I, like many others, was taught to block estrogen in men undergoing testosterone therapy if their levels seemed “too high.” I followed this practice without questioning it. But as I dove into the research, I discovered a mountain of evidence against it. I stopped routinely prescribing aromatase inhibitors (AIs), and the clinical results were remarkable. My male patients felt better, their erectile function improved, and their visceral fat decreased.

Much of testosterone’s positive impact on the cardiovascular and nervous systems comes from its conversion to estrogen. When you block this conversion, you block these critical benefits.

• Studies show that higher endogenous estrogen levels in men are associated with a reduced risk of cardiovascular disease.
• Estrogen plays a direct and vital role in endothelial function across individuals, helping regulate nitric oxide and improve vascular health.
• There are no standardized “normal” estrogen ranges for men; only expected ranges exist. A healthy young man with a robust testosterone level of 700-900 ng/dL will naturally have a higher estrogen level due to normal aromatase activity (around 7-10%). Trying to force this number down is counterproductive and harmful.

Estrogen and Breast Cancer: The Final Word

This brings us back to the biggest fear: breast cancer. The data is clear: 17-beta estradiol does not increase breast cancer risk. In fact, it’s protective.

• It is synthetic progestins, when combined with estrogen, that are implicated in increased breast cancer risk. The estrogen-only arm of the WHI protected women against breast cancer.
• A 2020 follow-up study published in JAMA, conducted by the original WHI authors, confirmed these findings over a 20-year period. Women who took estrogen-only had a significantly lower incidence of breast cancer and lower mortality from breast cancer. The group that took estrogen plus a progestin had a higher incidence of breast cancer (Chlebowski et al., 2020).
• Multiple studies have shown that estrogen therapy is safe for breast cancer survivors and does not increase the risk of recurrence or death. While each case must be handled with nuance and individual assessment, a history of breast cancer should not be an absolute contraindication for future hormone therapy.

For an excellent deep dive, I highly recommend the book “Estrogen Matters” by Dr. Avrum Bluming, an oncologist who witnessed the devastating effects of estrogen deprivation on his wife after her breast cancer treatment. He meticulously lays out the evidence showing that we have been giving our patients the worst possible advice by telling them they can never have hormones again.

Conclusion

I hope this overview has helped reframe your understanding of estrogen and hormone optimization. Estrogen is safe, profoundly beneficial, and essential for far more than just reproductive function. It is a key player in our immune system, a protector of our brain, bones, and heart, and it does not cause breast cancer. By moving beyond outdated fears and embracing the vast body of modern evidence, we can truly help our patients prevent disease, restore balance, and live longer, healthier lives. Thank you for your time, and I look forward to continuing this important conversation.

---

References

Ahmed, A. G. G., & El-Maraghy, N. N. (2023). Estrogen as an immunomodulator and neuroprotectant in fighting neurodegeneration. Molecular and Cellular Endocrinology, 561, 111836. https://doi.org/10.1016/j.mce.2022.111836

Carroll, J. C., & Pike, C. J. (2008). Selective estrogen receptor modulators and the brain: Effects on cognition and disease. Endocrine, Metabolic & Immune Disorders-Drug Targets, 8(2), 114–125. https://doi.org/10.2174/187153008784534346

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482

Davis, S. R., McCloud, P., Strauss, B. J. G., & Burger, H. (1999). Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas, 21(3), 227-236. https://doi.org/10.1016/s0378-5122(95)00918-3

Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241

Minkin, M. J., Reiter, S., & Maamari, R. (2017). The Black Box on the Package Insert for Estrogen: Is It Still Warranted? Gender and the Genome, 1(3), 133-143. https://doi.org/10.1089/gg.2017.0016

Mosconi, L., Gumb, T., Gonne, E., et al. (2017). Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery. PLoS ONE, 12(10), e0185926. https://doi.org/10.1371/journal.pone.0185926

Raval, A. P., Dave, K. R., & Pérez-Pinzón, M. A. (2015). Estradiol and the ischemic brain. American Journal of Physiology-Endocrinology and Metabolism, 309(5), E427–E434. https://doi.org/10.1152/ajpendo.00224.2015

Sørensen, M. B., Johansen, J. S., & Christiansen, C. (1990). The effect of combined estradiol and progesterone on bone mineral content and bone turnover. Bone, 11(6), 391-394. https://doi.org/10.1016/8756-3282(90)90117-g

St-Pierre, M. K., Moutevelis, K., & Bédard, S. (2022). Estrogen as a key player in the neurobiology of aging. Journal of Neuroendocrinology, 34(10), e13197. https://doi.org/10.1111/jne.13197

The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921

The Writing Group for the PEPI Trial. (1996). Effects of hormone replacement therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170025023